Outcomes of Re-Switching Anti–Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration
Korean Journal of Ophthalmology · 2025
DOI: 10.3341/kjo.2025.0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, 2025. Verfasst von Young Kun Suh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Visual Acuity, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University Bundang Hospital.
Abstract (Originalsprache)
Purpose
To investigate the anatomical and functional outcomes in cases of re-switching to previous anti?vascular endothelial growth factor (anti-VEGF) agents due to intraocular inflammation (IOI) following a switch to brolucizumab in neovascular age-related macular degeneration.
Methods
This study included patients with neovascular age-related macular degeneration who switched to brolucizumab and discontinued brolucizumab treatment due to IOI, with a follow-up duration of at least 6 months before and after brolucizumab treatment period. Changes in best-corrected visual acuity, central macular thickness, central choroidal thickness, and retinal fluid on optical coherence tomography were evaluated.
Results
A total of 16 eyes from 16 patients were reviewed. Two patients (12.5%) achieved complete fluid resolution before brolucizumab treatment, which increased to 15 (93.8%) during brolucizumab therapy. However, after switching back to other anti-VEGF agents, the proportion of patients with dry macula decreased to 37.5%. There were no statistically significant changes in best-corrected visual acuity, central macular thickness, central choroidal thickness throughout the study period.
Conclusions
In cases where brolucizumab treatment was discontinued due to IOI and switched back to other anti-VEGF agents, the anatomical response was insufficient, indicating the need for alternative treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Förderung
- Seoul National University Bundang Hospital
Zitieren
APA
Suh, Y. K., Lee, S. H., & Kim, M. S. (2025). Outcomes of Re-Switching Anti–Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2025.0008
Vancouver
Suh YK, Lee SH, Kim MS. Outcomes of Re-Switching Anti–Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. Korean Journal of Ophthalmology. 2025. doi:10.3341/kjo.2025.0008
BibTeX
@article{Suh2025,
author = {Suh, Young Kun and Lee, Seok Hee and Kim, Min Seok},
title = {Outcomes of Re-Switching Anti–Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration},
journal = {Korean Journal of Ophthalmology},
year = {2025},
doi = {10.3341/kjo.2025.0008}
}
EUVIMED